Imara, a clinical-stage biotechnology company, completed the merger with Enliven Therapeutics, a clinical-stage precision oncology company. Financial terms were not disclosed. “We are thrilled to complete this merger, which will accelerate the development of our differentiated pipeline of small molecule kinase inhibitors to address existing and emerging unmet needs in oncology. We are thankful to have stockholder support and a well-respected syndicate of new and existing investors. With a strong financial position, growing pipeline and experienced team, we are well positioned to achieve multiple clinical milestones with our two parallel lead programs and build a leading precision oncology company,” Sam Kintz, Enliven CEO.